On May, 8 The EPS for Penumbra, Inc. (PEN) Expected At $-0.02

April 16, 2018 - By Mark Mitchell

Penumbra, Inc. (NYSE:PEN) Corporate Logo

Investors expect Penumbra, Inc. (NYSE:PEN)’s quarterly earnings on May, 8., Zacks reports. Last year’s EPS was $-0.1, while now analysts expect change of 80.00 % up from current $-0.02 EPS. -120.00 % negative EPS growth is what Wall Street’s sees after $0.10 reported EPS last quarter. On during the last trading session the stock increased $0.9 or 0.74%, reaching $123.Penumbra, Inc. has volume of 124,074 shares. Since April 17, 2017 PEN has risen 41.68% and is uptrending. The stock outperformed the S&P 500 by 30.13%.

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally.The firm is valued at $4.20 billion. The firm offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, PX SLIM, and Velocity brands; aspiration based thrombectomy systems and accessory devices under the Penumbra System brand; and revascularization device for mechanical thrombectomy under the 3D brand.The P/E ratio is 946.15. It also provides neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands; and neurovascular stents for stent-assisted coiling in large and wide-neck aneurysms under the LIBERTY Stent brand.

Penumbra, Inc. (NYSE:PEN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.